2020 Guide to Patient Support Services

Merck

Merck Helps offers a full suite of support services that facilitate access to Merck’s drugs for eligible patients who are unable to afford their Merck medications, regardless of their insurance status.

Merck’s support services include the Merck Access Program and the Merck Patient Assistance Program.

Merck Access Program
This program provides eligible patients with access and support services, including insurance coverage for patients; benefits investigations, prior authorizations, and appeals; reimbursement; copay assistance for eligible patients; as well as referrals to Merck Patient Assistance Program.

Merck Patient Assistance Program
Eligible uninsured patients or those whose insurance does not cover their prescribed Merck medication may qualify to receive medication free of charge through MPAP.

Merck Co-pay Assistance Program
This program is available for patients with private health insurance who need assistance paying their copays for Keytruda (pembrolizumab).

Merck’s oncology and supportive care drugs are listed in the Table. For more information visit MerckHelps.com.

ELIGIBILITY

Merck Patient Assistance Program

Patients may qualify for Merck Patient Assistance Program, if:

  • They are legal residents of the United States or its territories
  • They have a prescription for a Merck medication from a licensed US healthcare provider
  • They are uninsured and/or do not have other forms of coverage for their prescription medicines
  • They are unable to afford their medication; specifically, for Emend capsules (aprepitant), Intron A (interferon alfa-2b, recombinant), Noxafil (posaconzole) or Sylatron (peginterferon alfa-2b), the patient’s household income must be ≤$49,960 for individuals, ≤$67,640 for couples, or ≤$103,000 for a family of 4.
  • For Emend for oral suspension (aprepitant) or Keytruda, the patient’s household income must be ≤$62,450 for 1 person, ≤$84,550 for couples, or ≤$128,750 for a family of 4.

Contact the individual programs directly for specific financial eligibility requirements.

Merck Access Program

MAP’s services are drug-specific for Emend for injection (fosaprepitant dimeglumine) and for Key­truda. Visit MerckAccessProgram.com or call 855-257-3932 for more information.

Merck Co-pay Assistance Program

The Merck Co-pay Assistance Program is available for patients:

  • Who are aged >18 years
  • Who have been prescribed a qualified Merck medication (Keytruda) for an FDA-approved indication
  • With private health insurance that provides coverage for the prescribed medication
  • Who meet certain financial ­requirements.

This program is not valid for patients covered under a government-­funded program or uninsured patients. Patients must pay the first $25 of copay per administration of their drug, up to a maximum of $25,000 per patient per calendar year.

APPLICATION & ENROLLMENT

To enroll in Merck Access Program, programs, including the Merk Patient Assistance Program and the Merck Co-pay Assistance Program, patients must complete the relevant sections of the enrollment form with their healthcare provider (available at MerckAccessProgram.com), and fax it to 855-755-0518 or mail it to the address provided on the form.

The prescribed Merck medication (Emend for oral suspension or Keytruda), and the program the patient is applying for, must be indicated on the form. The patient’s insurance information and clinical information (including a diagnostic code) must be included.

The patient’s gross household income (including before-tax wages, pension, interest/dividends, Social Security benefits, and any other sources of income) must be supplied if the patient is applying for the Merck Patient Assistance Program or the Merck Co-pay Assistance Program. Patients who qualify for the program are eligible to receive their medications at no cost for up to 1 year.

TABLE MERCK ONCOLOGY/SUPPORTIVE CARE DRUGS

Drugs
Indications
Patient support programs

Drug
Emend capsules (aprepitant)
Indications
Nausea and vomiting caused by chemotherapy
Patient support program

Drug
Emend for oral suspension (aprepitant)
Indications
Nausea and vomiting caused by chemotherapy
Patient support programs

Drug
Emend for injection (fosaprepitant dimeglumine)
Indications
Nausea and vomiting caused by chemotherapy
Patient support program

Drug
Intron A (interferon alfa-2b, recombinant) for injection
Indications
Hairy-cell leukemia; malignant melanoma; follicular lymphoma; AIDS-related Kaposi’s sarcoma
Patient support program

Drug
Keytruda (pembrolizumab)
Indications
Patient support programs

Drug
Noxafil (posaconazole)
Indications
Invasive Aspergillus and Candida infections associated with hematologic cancer or stem-cell transplantation
Patient support program

Drug
Sylatron (peginterferon alfa-2b)
Indications
Melanoma
Patient support program

dMMR indicates mismatch repair–deficient; MSI-H, microsatellite instability-high; NSCLC, non–small-cell lung cancer.

Keytruda (pembrolizumab) Indications

Unresectable or metastatic melanoma or melanoma with lymph node involvement after complete resection; metastatic NSCLC with high PD-L1 expression and no EGFR or ALK mutations; first-line treatment of metastatic nonsquamous NSCLC with no EGFR or ALK mutations, in combination with pemetrexed and platinum chemotherapy; metastatic NSCLC with PD-L1 and disease progression during or after platinum-containing chemotherapy; metastatic nonsquamous NSCLC with no EGFR or ALK mutations, in combination with pemetrexed and platinum-containing chemotherapy; metastatic squamous NSCLC, in combination with carboplatin plus paclitaxel or nab-paclitaxel; metastatic small-cell lung cancer after progression with platinum-based chemotherapy; first-line treatment of unresectable/recurrent head and neck squamous-cell carcinoma; recurrent/metastatic head and neck squamous-cell cancer that progressed during or after platinum-containing chemotherapy; refractory/relapsed classical Hodgkin lymphoma; refractory primary mediastinal large B-cell lymphoma, or relapsed disease after ≥2 lines of therapy; locally advanced/metastatic urothelial carcinoma with PD-L1 expression, as determined by an FDA-approved test, in patients ineligible for cisplatin-containing chemotherapy, or in patients ineligible for platinum-containing chemotherapy, regardless of PD-L1 status; locally advanced or metastatic urothelial carcinoma that progressed during or after platinum-containing chemotherapy, or within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy; unresectable or metastatic MSI-H or dMMR solid tumors progressing after treatment; unresectable or metastatic MSI-H or dMMR colorectal cancer that progressed after treatment with fluoropyrimidine, oxaliplatin, and irinotecan; advanced endometrial carcinoma that is not MSI-H or dMMR progressing after systemic therapy and who are not candidates for curative surgery or radiation, in combination with lenvatinib; recurrent locally advanced/metastatic gastric or gastroesophageal junction adenocarcinoma with PD-L1 expression and disease progression during or after ≥2 therapies, including fluoropyrimidine- and platinum-containing chemotherapy, and, if appropriate, HER2-targeted therapy; advanced esophageal squamous-cell cancer; recurrent or metastatic cervical cancer progressing with PD-L1 expression during or after chemotherapy; hepatocellular carcinoma after sorafenib therapy; recurrent locally advanced or metastatic Merkel-cell carcinoma; first-line treatment of advanced renal-cell carcinoma, in combination with axitinib

Report Broken Links

Have you encountered a problem with a URL (link) on this page not working or displaying an error message?

Help us fix it! Report broken links here.

Report Broken Link

Subscribe to
Oncology Practice Management

Stay up to date with oncology news & updates by subscribing to recieve the free OPM print publications or weekly e‑Newsletter.

I'd like to recieve: